(Q40164346)

18 September 2017

1 reference

title

Pharmacology, clinical efficacy and adverse effects of vindesine sulfate, a new vinca alkaloid (English)

1 reference

18 September 2017

Pharmacology, Clinical Efficacy and Adverse Effects of Vindesine Sulfate, A New Vinca Alkaloid (English)

1 reference

https://api.crossref.org/works/10.1002/J.1875-9114.1983.TB03269.X

7 October 2023

1 reference

R. J. Cersosimo

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6359081

7 October 2023

R. Bromer

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6359081

7 October 2023

J. T. Licciardello

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6359081

7 October 2023

W. K. Hong

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6359081

7 October 2023

language of work or name

English

0 references

publication date

1 September 1983

1 reference

full work available at URL

18 September 2017

http://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fj.1875-9114.1983.tb03269.x

1 reference

https://api.crossref.org/works/10.1002/J.1875-9114.1983.TB03269.X

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fj.1875-9114.1983.tb03269.x

7 October 2023

1 reference

https://api.crossref.org/works/10.1002/J.1875-9114.1983.TB03269.X

https://onlinelibrary.wiley.com/doi/full/10.1002/j.1875-9114.1983.tb03269.x

7 October 2023

1 reference

https://api.crossref.org/works/10.1002/J.1875-9114.1983.TB03269.X

7 October 2023

1 reference

18 September 2017

volume

3

1 reference

18 September 2017

issue

5

1 reference

18 September 2017

page(s)

259-274

1 reference

Vindesine a short review of preclinical and first clinical data

18 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03269.X

The comparative clinical pharmacology and pharmacokinetics of vindesine, vincristine, and vinblastine in human patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03269.X

Clinical pharmacokinetics of vindesine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03269.X

Phase I anti-cancer agents: vindesine (desacetyl vinblastine amide sulfate).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03269.X

Vindesine: a phase II study in childhood malignancies-a report for cancer and leukemia group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03269.X

Vindesine a review of phase-II trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03269.X

Vindesine and prednisone for remission induction in children with acute lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03269.X

Phase-II trial with vindesine for regression induction in patients with leukemias and hematosarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03269.X

An initial report of a phase-III trial comparing vindesine and vincristine for acute lymphocytic leukemia of childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03269.X

Phase I evaluation of vindesine in children: a Southwest Oncology Group pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03269.X

Relation of “lymphoid” phenotype and response to chemotherapy incorporating vincristine-prednisolone in the acute phase of Ph1 positive leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03269.X

Terminal Transferase as a Predictor of Initial Responsiveness to Vincristine and Prednisone in Blastic Chronic Myelogenous Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03269.X

Phase II trial of vindesine in breast cancer, lymphoma and other tumors: future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03269.X

Phase II trial of vindesine in advanced neoplastic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03269.X

Vindesine chemotherapy in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03269.X

Therapy of advanced squamous carcinoma of the lung: cyclophosphamide vesus "COMB".

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03269.X

Vincristine (NSC 67574) in non-small cell bronchogenic carcinoma. Results of a phase II clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03269.X

Evaluation of vindesine and MER in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03269.X

Current status of the therapy of advanced renal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03269.X

Vindesine in the treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03269.X

Vindesine a clinical trial with special reference to neurological side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03269.X

Inapparent infiltrations associated with vindesine administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1983.TB03269.X

Comparative cell killing and kinetic effects of vincristine or vindesine in mammalian cell lines

21 January 2018

4

1 reference

https://api.crossref.org/works/10.1002/J.1875-9114.1983.TB03269.X

Pharmacokinetics of vindesine and vincristine in humans

7 October 2023

7

1 reference

https://api.crossref.org/works/10.1002/J.1875-9114.1983.TB03269.X

Phase II trial of vindesine in patients with malignant lymphoma

7 October 2023

32

1 reference

https://api.crossref.org/works/10.1002/J.1875-9114.1983.TB03269.X

Broad phase II study of vindesine

7 October 2023

42

1 reference

https://api.crossref.org/works/10.1002/J.1875-9114.1983.TB03269.X

Vindesine (VDS) monochemotherapy for non-small cell lung cancer: a report of 45 cases

7 October 2023

45

1 reference

https://api.crossref.org/works/10.1002/J.1875-9114.1983.TB03269.X

Vindesine in the treatment of squamous cell carcinoma, adenocarcinoma, and large cell carcinoma of the lung

7 October 2023

46

1 reference

https://api.crossref.org/works/10.1002/J.1875-9114.1983.TB03269.X

Vindesine: an effective agent in the treatment of non-small cell lung cancer

7 October 2023

48

1 reference

https://api.crossref.org/works/10.1002/J.1875-9114.1983.TB03269.X

Clinical studies of vinblastine

7 October 2023

53

1 reference

https://api.crossref.org/works/10.1002/J.1875-9114.1983.TB03269.X

Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: A randomized trial investigating two dosage schedules

7 October 2023

59

1 reference

https://api.crossref.org/works/10.1002/J.1875-9114.1983.TB03269.X

Cisplatin, doxorubicin, cyclophosphamide, and vindesine combination chemotherapy for non-small cell lung cancer

7 October 2023

62

1 reference

https://api.crossref.org/works/10.1002/J.1875-9114.1983.TB03269.X

Extensive adenocarcinoma and large cell undifferentiated carcinoma of the lung treated with 5-FU, vindesine, and mitomycin (FEMi): a Southwest Oncology Group Study

7 October 2023

63

1 reference

https://api.crossref.org/works/10.1002/J.1875-9114.1983.TB03269.X

Phase II trial of vindesine in patients with small cell lung carcinoma

7 October 2023

66

1 reference

https://api.crossref.org/works/10.1002/J.1875-9114.1983.TB03269.X

Phase II trial of vindesine in patients with malignant melanoma

7 October 2023

73

1 reference

https://api.crossref.org/works/10.1002/J.1875-9114.1983.TB03269.X

Update results of vindesine as a single agent in the therapy of advanced malignant melanoma

7 October 2023

77

1 reference

https://api.crossref.org/works/10.1002/J.1875-9114.1983.TB03269.X

Vindesine: a phase II study in the treatment of breast carcinoma, malignant melanoma, and other tumors

7 October 2023

78

1 reference

https://api.crossref.org/works/10.1002/J.1875-9114.1983.TB03269.X

Phase II trial of vindesine in advanced head and neck cancer

7 October 2023

86

1 reference

https://api.crossref.org/works/10.1002/J.1875-9114.1983.TB03269.X

Continuous vindesine infusion in advanced head and neck cancer

7 October 2023

89

1 reference

https://api.crossref.org/works/10.1002/J.1875-9114.1983.TB03269.X

Phase II evaluation of vindesine for patients with advanced colorectal carcinoma

7 October 2023

91

1 reference

https://api.crossref.org/works/10.1002/J.1875-9114.1983.TB03269.X

Phase II evaluation of vindesine in patients with advanced colorectal carcinoma

7 October 2023

92

1 reference

https://api.crossref.org/works/10.1002/J.1875-9114.1983.TB03269.X

Vindesine in the treatment of esophageal carcinoma: a phase II study

7 October 2023

98

1 reference

https://api.crossref.org/works/10.1002/J.1875-9114.1983.TB03269.X

Cisplatin, vindesine, and bleomycin (DVB) combination chemotherapy for esophageal carcinoma

7 October 2023

101

1 reference

https://api.crossref.org/works/10.1002/J.1875-9114.1983.TB03269.X

Phase II evaluation of vindesine in patients with advanced breast cancer

7 October 2023

102

1 reference

https://api.crossref.org/works/10.1002/J.1875-9114.1983.TB03269.X

Phase II study of vindesine in patients with advanced breast cancer

7 October 2023

107

1 reference

https://api.crossref.org/works/10.1002/J.1875-9114.1983.TB03269.X

Vinblastine given as a continuous 5-day infusion in the treatment of refractory advanced breast cancer

7 October 2023

109

1 reference

https://api.crossref.org/works/10.1002/J.1875-9114.1983.TB03269.X

A comparison of combination chemotherapy using vindesine or vincristine with adriamycin in the treatment of advanced breast carcinoma

7 October 2023

112

1 reference

https://api.crossref.org/works/10.1002/J.1875-9114.1983.TB03269.X

A comparison of vindesine administration by bolus injection and by 24-hour infusion

7 October 2023

115

1 reference

https://api.crossref.org/works/10.1002/J.1875-9114.1983.TB03269.X

Phase II study of vindesine sulfate in the therapy for advanced renal carcinoma

7 October 2023

117

1 reference

https://api.crossref.org/works/10.1002/J.1875-9114.1983.TB03269.X

Initial clinical studies of vindesine

7 October 2023

118

1 reference

https://api.crossref.org/works/10.1002/J.1875-9114.1983.TB03269.X

7 October 2023

Identifiers

1 reference

18 September 2017

1 reference